3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020. Third Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September 30, 2020. Total operating income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NI

JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company. Continue Reading BiondVa

JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorro

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million compared with $1.97 million for the three months ended June 30, 2022.Marketing, general and administrative expenses for the three months ended June 30, 2

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for con

LOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell's latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). BiondVax's pipeline is based on an innovative platform technology of alpaca-derived nanosized ant

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis.BiondVax to lead development and commercialization of NanoAbs with potential to neutralize IL-17A, IL-17F and IL-17A/F isoforms with high potency; ex vivo proof-of-concept expected this year, in vivo early next year.Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.Adds to BiondVax's pipeline of bio-better antibodies targeting diseases with large unmet medical needs, attractive commercial

JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its full-year financial results for the year ended December 31, 2022, and provided a business update. At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission. Business Update & Recent Highlights In late 2021 and early 2022, BiondVax signed definitive agreements with the Max Planck Society (MPG) and the University Medical

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.  Presentation Details: Date: Tuesday, March 21, 2023Time: 11:30 a.m.Location: Mes

LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), recently appeared on the popular Test. Optimize. Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. The broadcast, hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency, is available for on-demand listening on Test. Optimize. Scale. To begin the interview, Reichman discussed his professional journey leading up to joining Bi

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The conference is taking place Feb. 6-9, 2023, in New York. Reichman's presentation will focus on recent successful preclinical in vivo results of BiondVax's innovative inhaled COVID-19 treatment and additional pipeline plans, including nanosized VHH-antibodies (NanoAbs) for the treatment of au

COVID-19 illness was virtually prevented in hamsters administered BiondVax's inhaled NanoAb and infected three hours later with SARS-CoV-2  Data further strengthens value proposition of BiondVax's COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data indicated NanoAb treatment one day post infection led to significantly milder illness, faster recovery, and lower viral lung titer in comparison to the placebo groupFirst-in-human Phase 1/2a clinical trial is planned for 2023The COVID-19 NanoAb is BiondVax's first in a new pipeline of innovative NanoAb drugs addressing diseases with large underserved medical needs and attractive commercial opportunities such as psoriasi

Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00

EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

D - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

424B3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

424B3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)